Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial

Inflammatory Bowel Disease

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

BMC Gastroenterol.

Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO, Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators., European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP)

doi: 10.1186/s12876-019-0992-2.

Inflammatory Bowel Disease

High-intensity interval training and moderate-intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial

BMC Gastroenterol.

Tew GA, Leighton D, Carpenter R, Anderson S, Langmead L, Ramage J, Faulkner J, Coleman E, Fairhurst C, Seed M, Bottoms L

doi: 10.1186/s12876-019-0936-x.

Inflammatory Bowel Disease

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease

Inflamm Bowel Dis.

George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V

doi: 10.1093/ibd/izz193.

Inflammatory Bowel Disease

Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data from 5 Randomized Controlled Induction Trials

Clin Gastroenterol Hepatol.

Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V

doi: 10.1016/j.cgh.2019.08.025.

Inflammatory Bowel Disease

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Gut.

Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR

doi: 10.1136/gutjnl-2019-318256.

Inflammatory Bowel Disease

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial

J Crohns Colitis

Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ

doi: 10.1093/ecco-jcc/jjab133

Inflammatory Bowel Disease

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Lancet Gastroenterol Hepatol.

Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G

doi: 10.1016/S2468-1253(20)30188-6.

ECCO 2019

Paediatric Crohn’s disease

Assa A et al. 2019. Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial. Oral presentation at: ECCO 2019 Congress; 6–9 March; Copenhagen, Denmark.

Inflammatory Bowel Disease

Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial

Gastroenterology.

Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamali H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J

doi: 10.1053/j.gastro.2019.04.021.

Related content

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

High-intensity interval training and moderate-intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease

Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data from 5 Randomized Controlled Induction Trials

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Paediatric Crohn’s disease

Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial